Citation, DOI & article data
Paragangliomas, sometimes called glomus tumors, are rare neuroendocrine tumors arising from paraganglia.
Paraganglia are clusters of neuroendocrine cells dispersed throughout the body and closely related to the autonomic nervous system, with either parasympathetic or sympathetic function. The largest cluster of cells is found within the adrenal medulla, with smaller collections in the paravertebral space, and head and neck region. Tumor arising in the paraganglia are called paragangliomas. They are classified by both location and secretory function.
Sympathetic paragangliomas present with features of catecholamine-excess, such as headaches, palpitations, diaphoresis and hypertension. Whereas, parasympathetic paragangliomas present more commonly with mass-effect such as cranial nerve palsies, a neck mass or tinnitus.
All paragangliomas consist of two types of cells; type I and type II. The main components are lobules or nests of chief cells (type I); these structures are known as Zellballen. They are surrounded by a single layer of sustentacular cells (type II) 4.
Malignancy is defined as evidence of metastases. Histologically there are no reliable markers of malignant potential. Most common sites for malignancy include lymph nodes, liver, lung, and bone 5.
Risk of malignancy:
- pheochromocytoma: 10%
- sympathetic paraganglioma: 20%
- parasympathetic paraganglioma: 2-20%
It is important to note biopsy (incision or fine needle aspirate) is contraindicated in suspected paragangliomas until biochemical screening is negative for catecholamine excess, due to the risk of catecholamine crisis and severe hypertension.
Parasympathetic paragangliomas arise within paraganglia of the head and neck (see - paragangliomas of the head and neck) in association with the branches of the glossopharyngeal and vagus nerve 1. They are generally non-secretory.
- carotid body paraganglioma
- jugulotympanic paraganglioma
- glomus jugulare paraganglioma
- glomus tympanicum paraganglioma
- glomus vagale paraganglioma
- laryngeal paraganglioma
Sympathetic paragangliomas generally arise in paraganglia below the level of the neck. They tend to secrete catecholamines and can be intra- or extra-adrenal.
extra-adrenal: arise outside the adrenal gland along the length of the sympathetic chain 2
- organ of Zuckerkandl
- bladder base
- thorax (see mediastinal paraganglioma)
- paravertebral (aortosympathetic paraganglia)
- great vessels of the chest (aortopulmonary paraganglia)
- cardiac (extremely rare; may be located along the epicardium, in the atrial cavity, the interatrial septum or the ventricles) 3
- intra-adrenal: arise within the adrenal medulla
Immunohistochemical examination confirms neuroendocrine differentiation of chief cells (type I):
Sustentacular cells (type II):
Paragangliomas are the most strongly hereditary group of tumors. The most common genetic cause of hereditary paragangliomas are mutations in the succinate dehydrogenase (SDH) subunit (genes: SDHB, SDHD, SDHA or SDHAF2) 2.
They are also associated with four clinical syndromes:
- von Hippel-Lindau syndrome
- multiple endocrine neoplasia types 2A and 2B
- neurofibromatosis type 1
- Carney-Stratakis syndrome
von Hippel-Lindau syndrome and neurofibromatosis type 1 are more commonly associated with pheochromocytomas. SDH mutations are common in head and neck paragangliomas, except for SDHB, which is associated with sympathetic paragangliomas. SDHB also confers a higher risk of malignancy 2.
Both anatomical and functional imaging of paragangliomas is required for diagnosis and staging. Anatomical imaging includes CT and MRI. Multiple functional imaging modalities exist: 123I-MIBG scintigraphy, 18F-FDA PET, 18F-DOPA PET, 18F-FDG PET and 68Ga-DOTATATE PET.
CT and MRI are the initial imaging modalities for tumor localization. They have excellent sensitivity but lack specificity in unequivocally identifying a mass as a paraganglioma.
- density greater than 10 HU on non-contrast imaging (differentiates from adenoma)
- avidly enhances with contrast with delayed washout (due to rich capillary network)
- can detect lesions 0.5 cm in diameter 6
- hypointense to liver and adrenal
- salt and pepper appearance due to enhancing parenchyma (salt) and signal flow voids of vessels (pepper)
- hyperintense 'light bulb' appearance
- salt and pepper enhancement also seen 7
- T1 C+ (Gd): heterogenous prolonged enhancement
Targets for functional imaging:
- tumor-specific catecholamine production: 123I-MIBG, 18F-FDA and 18F-DOPA
- glucose: 18F-FDG
- somatostatin receptor (overexpressed in paragangliomas): 68Ga-DOTATATE
Each modality has strengths and weaknesses in detecting lesions depending on their location, secretory function and underlying genetic mutation.
- strength: pheochromocytomas and extra-adrenal sympathetic paragangliomas 8
- weakness: head and neck, malignant disease, MEN2 9
- strength: head and neck paragangliomas, SDHD-mutations, non-metastatic disease 8,10
- weakness: SDHB mutations 11
- strength: metastatic disease, non-metastatic pheochromocytomas 12
- weakness: limited clinical availability
- strength: malignancy, SHDB-mutations, von Hippel-Lindau syndrome 8,13
- weakness: may lack specificity
- strength: overall viable imaging modality; proven superiority in sporadic disease, SHDB-mutations, head and neck lesions 14-16
- weakness: detection of liver and lung lesions
Treatment and prognosis
Treatment may include surgical resection or radiotherapy. Paragangliomas may metastasize to other locations.
Differential diagnosis differs depending on the location and histology of the paraganglioma but can include 17:
- 1. Williams M. Paragangliomas of the Head and Neck: An Overview from Diagnosis to Genetics. Head Neck Pathol. 2017;11(3):278-87. doi:10.1007/s12105-017-0803-4 - Pubmed
- 2. Lam A. Update on Adrenal Tumours in 2017 World Health Organization (WHO) of Endocrine Tumours. Endocr Pathol. 2017;28(3):213-27. doi:10.1007/s12022-017-9484-5 - Pubmed
- 3. Grebenc M, Rosado de Christenson M, Burke A, Green C, Galvin J. Primary Cardiac and Pericardial Neoplasms: Radiologic-Pathologic Correlation. Radiographics. 2000;20(4):1073-103; quiz 1110-1, 1112. doi:10.1148/radiographics.20.4.g00jl081073 - Pubmed
- 4. International Agency for Research on Cancer, Otmar D. Wiestler. WHO Classification of Tumours of the Central Nervous System. (2016) ISBN: 9789283244929 - Google Books
- 5. Fliedner S, Lehnert H, Pacak K. Metastatic Paraganglioma. Semin Oncol. 2010;37(6):627-37. doi:10.1053/j.seminoncol.2010.10.017 - Pubmed
- 6. Baez J, Jagannathan J, Krajewski K et al. Pheochromocytoma and Paraganglioma: Imaging Characteristics. Cancer Imaging. 2012;12(1):153-62. doi:10.1102/1470-7330.2012.0016 - Pubmed
- 7. Blake M, Kalra M, Maher M et al. Pheochromocytoma: An Imaging Chameleon. Radiographics. 2004;24 Suppl 1(suppl_1):S87-99. doi:10.1148/rg.24si045506 - Pubmed
- 8. Timmers H, Taieb D, Pacak K. Current and Future Anatomical and Functional Imaging Approaches to Pheochromocytoma and Paraganglioma. Horm Metab Res. 2012;44(5):367-72. doi:10.1055/s-0031-1299712 - Pubmed
- 9. Bhatia K, Ismail M, Sahdev A et al. 123I-Metaiodobenzylguanidine (MIBG) Scintigraphy for the Detection of Adrenal and Extra-Adrenal Phaeochromocytomas: CT and MRI Correlation. Clin Endocrinol (Oxf). 2008;69(2):181-8. doi:10.1111/j.1365-2265.2008.03256.x - Pubmed
- 10. Hoegerle S, Ghanem N, Altehoefer C et al. 18F-DOPA Positron Emission Tomography for the Detection of Glomus Tumours. Eur J Nucl Med Mol Imaging. 2003;30(5):689-94. doi:10.1007/s00259-003-1115-3 - Pubmed
- 11. Treglia G, Cocciolillo F, de Waure C et al. Diagnostic Performance of 18F-Dihydroxyphenylalanine Positron Emission Tomography in Patients with Paraganglioma: A Meta-Analysis. Eur J Nucl Med Mol Imaging. 2012;39(7):1144-53. doi:10.1007/s00259-012-2087-y - Pubmed
- 12. Timmers H, Chen C, Carrasquillo J et al. Comparison of 18F-Fluoro-L-DOPA, 18F-Fluoro-Deoxyglucose, and 18F-Fluorodopamine PET and 123I-MIBG Scintigraphy in the Localization of Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab. 2009;94(12):4757-67. doi:10.1210/jc.2009-1248 - Pubmed
- 13. Timmers H, Kozupa A, Chen C et al. Superiority of Fluorodeoxyglucose Positron Emission Tomography to Other Functional Imaging Techniques in the Evaluation of Metastatic SDHB-Associated Pheochromocytoma and Paraganglioma. J Clin Oncol. 2007;25(16):2262-9. doi:10.1200/JCO.2006.09.6297 - Pubmed
- 14. Janssen I, Chen C, Millo C et al. PET/CT Comparing (68)Ga-DOTATATE and Other Radiopharmaceuticals and in Comparison with CT/MRI for the Localization of Sporadic Metastatic Pheochromocytoma and Paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43(10):1784-91. doi:10.1007/s00259-016-3357-x - Pubmed
- 15. Janssen I, Blanchet E, Adams K et al. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2015;21(17):3888-95. doi:10.1158/1078-0432.CCR-14-2751 - Pubmed
- 16. Janssen I, Chen C, Taieb D et al. 68Ga-DOTATATE PET/CT in the Localization of Head and Neck Paragangliomas Compared with Other Functional Imaging Modalities and CT/MRI. J Nucl Med. 2016;57(2):186-91. doi:10.2967/jnumed.115.161018 - Pubmed